{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"FUMANBA-2","nct_id":"NCT05181501","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fumanba-2-nct05181501. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection（CT103A）will be infused at 1.0 x 10\\^6 CAR+ T cells/kg in newly diagnosed subjects with high-risk multiple myeloma","label":"CT103A in Newly Diagnosed Subjects With High-risk Multiple Myeloma","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2039-04","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":20,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)","otherNames":["CT103A"],"type":"DRUG"}],"last_update":"2022-01-06","lead_sponsor":"Nanjing IASO Biotechnology Co., Ltd.","official_title":"A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2024-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Proportion of Minimal Residual Disease (MRD)-negative subjects","timeFrame":"Up to 2 years after CT103A infusion"},{"measure":"Median progression-free survival (mPFS)","timeFrame":"Up to 2 years after CT103A infusion"}],"references":[],"start_date":{"date":"2022-04","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)","url":"https://clinicaltrials.gov/study/NCT05181501"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fumanba-2-nct05181501"}